Skip to main content
. Author manuscript; available in PMC: 2021 Jun 3.
Published in final edited form as: J Pediatr. 2021 Jan 22;232:264–271. doi: 10.1016/j.jpeds.2021.01.043

Table II.

Differences among children with ASD in the SEED who did and did not use psychotropic medication

ASD with psychotropic medication use (n = 62) ASD without psychotropic medicatiuse (n = 701)
Characteristics No. (%) No. (%) χ2 (P value) Cramer V
ADI-R self-injurious behavior 5.72 (.02) 0.09
 No 21 (33.9) 348 (49.7)
 Yes 41 (66.1) 352 (50.3)
CBCL aggressive behavior 8.72 (<.01) 0.11
 No 37 (59.7) 536 (76.6)
 Yes 25 (40.3) 164 (23.4)
CBCL anxious/depressed 1.17 0.28
 No 55 (88.7) 584 (83.4)
 Yes 7 (11.3) 116 (16.6)
CBCL attention problems 38.5 (<.01) 0.23
 No 8 (12.9) 378 (54.0)
 Yes 54 (87.1) 322 (46.0)
CBCL emotional reactivity 1.23 (.27) 0.04
 No 32 (51.6) 412 (58.9)
 Yes 30 (48.4) 288 (41.1)
CBCL sleep problems 3.79 (.05) 0.10
 No 43 (69.4) 559 (79.9)
 Yes 19 (30.6) 141 (20.1)
Child sex 0.27 (.73) 0.02
 Male 52 (83.9) 569 (81.2)
 Female 10 (16.1) 132 (18.8)
MSEL low developmental level
 No 13 (21.7) 259 (37.3) 5.87 (.02) 0.10
 Yes 47 (78.3) 435 (62.7)
SRS moderate to severe restricted interests and repetitive behaviors
 No 11 (18.0) 225 (32.4) 5.40 (.02) 0.10
 Yes 50 (82.0) 469 (67.6)
SRS moderate to severe total ASD symptoms
 No 8 (13.1) 189 (27.2) 5.80 (.02) 0.10
 Yes 53 (86.9) 505 (72.8)
Study site 17.0 (<.01) 0.15
 CA 8 (12.9) 115 (16.4)
 CO 3 (4.8) 126 (18.0)
 GA 21 (33.9) 125 (17.8)
 MD 14 (22.6) 131 (18.7)
 NC 12 (19.3) 110 (15.7)
 PA 4 (6.5) 94 (13.4)

CBCL, Child Behavior Checklist 1½–5.

Bold indicates statistical significance at P ≤ .05. A Cramer V estimate of ≥0.20 is needed to assume a meaningful effect of medication use.

ADI-R, n = 700 for children without medication use; CBCL, n = 700 for children without medication use; MSEL, n = 60 for children with medication use and 694 for children without medication use; SRS, n = 61 for children with medication use and 694 for children without medication use.